Aoxing Pharmaceutical Comp. Inc. (AOXG)

[deri21]

JERSEY CITY, NJ / ACCESSWIRE / November 4, 2015 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced that one of its products, Xiongju Shangqing Tablet, has been included in the government essential drug procurement lists for nine Chinese provinces: Shanghai, Qinghai, Gansu, Hubei, Shanxi, Anhui, Sichuan, Jilin and Inner Mongolia. The combined population of these nine provinces is approximately 400 million, representing a significant potential market.

The Xiongju Shangqing Tablet is indicated for treatment of migraine, toothache and sore throat, as well as flu-related pain, fever and runny nose. Hebei Aoxing, the operating subsidiary of Aoxing Pharma, is one of only three pharmaceutical companies licensed to produce the Xiongju Shangqing Tablet in China.

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China Food and Drug Administration ("CFDA"). For more information, please visit: www.aoxingpharma.com.